Literature DB >> 2528739

A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.

L A Emtage1, C Trethowan, K Kelly, D Arkell, D M Wallace, M Hughes, A Hay, R Blacklock, M Jones, A Rouse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2528739

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  2 in total

Review 1.  Estrogen therapy in patients with prostate cancer: a contemporary systematic review.

Authors:  Leonardo Oliveira Reis; Emerson Luis Zani; Herney Andrés García-Perdomo
Journal:  Int Urol Nephrol       Date:  2018-03-29       Impact factor: 2.370

Review 2.  Optimal management of recurrent prostate cancer in older patients.

Authors:  Elizabeth R Kessler; Thomas W Flaig
Journal:  Drugs Aging       Date:  2012-11       Impact factor: 3.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.